First Low-Molecular-Weight Heparin for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer: FRAGMIN®, Approved by the USFDA
The USFDA has approved a new indication for FRAGMIN® (dalteparin sodium injection): extended treatment of symptomatic venous thromboembolism (VTE) [proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE)] to reduce the recurrence of VTE in cancer patients.
In the United States, FRAGMIN is also indicated for the following:
prevention of DVT, which may lead to PE (pulmonary embolism), in patients undergoing hip replacement surgery, in at- risk patients undergoing abdominal surgery and in at-risk acutely ill patients whose mobility is severely restricted- prophylaxis of ischemic complications resulting from unstable angina and non- Q-wave myocardial infarction (heart attack), when used with aspirin
Exclusively licensed by Eisai, Inc. from Pfizer, Inc. for U.S. distribution, FRAGMIN® is the first low-molecular- weight heparin (LMWH) approved in the U.S. for the extended treatment of recurrent VTE in patients with cancer.
Find more details from the full report.
Comment Preview